BCRB 2018

19/09/2018

EGFR inhibition + RCT in rectal cancer

• Relatively low pCR in pts receiving cetuximab along with CRT as preop R\ in rectal cancer in phase I/II

Cetuximab, capecitabine, and RT

Cetuximab, capecitabine, oxaliplating and RT

Rödel C Int J Radiat Oncol Biol Phys 2008

Machiels Ann Oncol 2007

pCR = 5% (2/37)

pCR = 9% (4/45)

25

EGFR inhibition + RCT in rectal cancer

• Importance of translational research

26

Debucquoy JCO 2009

13